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Background and objectives: The objective of this study is to synthesize and evaluate
1-(4-chlorophenyl)-4-(4-hydroxy-3-methoxy-5-nitrobenzylidene) pyrazolidine-3,5-dione
(CD59) analogues to establish structure–activity relationship and mechanism of action.
Methods: Thirty analogues of reported antitubercular CD59 were prepared by two-step
synthetic protocols and characterized. The compounds were evaluated for in vitro activ-
ities against Mycobacterium tuberculosis (MTB), cytotoxicity against RAW 264.7 cells. The
molecules were also evaluated for three mycobacterial enzymes to study the mechanism
of action.
Results: Among the compounds, 4-(2-bromobenzylidene)-1-(4-chlorophenyl)pyrazoli-
dine-3,5-dione (4k) was found to be the most active compound in vitro with MICs of
4.13 lM against log-phase culture of MTB and also non-toxic up to 50 lM.
Conclusions: Amongst all, the compounds 4g, 3i and 3n were most active against the
enzymes MTB Pantothenate synthetase, lysine amino transferase and Alanine dehydro-
genase, respectively. Further screening of these molecules was required in the in vitro dor-
mant MTB models.
 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Introduction
Tuberculosis (TB) is an infection that mainly affects the lungs
and is caused by the pathogen Mycobacterium tuberculosis
(MTB). In 2010, the World Health Organization estimated
8.8 million new cases of TB worldwide [1]. Since the disease
remains a global health crisis with an alarming rise of mul-ti-drug resistant and extensively drug resistant [2] bacterial
strains, the need for new antitubercular therapeutics is very
urgent. Target-based approaches are widely used in drug dis-
covery; questions have been raised about the efficiency of this
approach given the very high attrition rates that these pro-
jects have historically shown in the anti-infective field [3].
This situation becomes particularly alarming when consider-
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discovery. Furthermore, the state of affairs is a symptom of
wider inconsistencies between results obtained with animal
models of infection and their translation to clinical therapeu-
tic value in humans. Compounds identified in whole-cell
screens fulfil a double function: (a) they provide lead struc-
tures for further optimization within the drug development
progression sequence, and (b) they can be exploited as tools
to identify new targets. Notably, cell-based hits already fulfil
some important criteria, including permeability issues and,
given the progression criteria in the high-throughput screen,
higher activity against mycobacteria than mammalian cells.
Thus, they provide suitable chemical and biological starting
points. Recently, William R. Jacobs, Jr. et al. [4] used a subset
of a chemical library composed of 300 compounds inhibiting
Plasmodium falciparum enoyl reductase, and tested it against
MTB. Among them, one of the molecule CD59 (1-(4-chloro-
phenyl)-4-(4-hydroxy-3-methoxy-5-nitrobenzylidene) pyraz-
olidine-3,5-dione) showed good activity against MTB with
minimum inhibitory concentration (MIC) of 1.5 lM (Fig. 1).
CD59 was taken as the starting point to design more ana-
logues by keeping pyrazolidine-3,5-dione nucleus intact and
modify 1st and 4th positions with various aryl and heteroaryl
moiety to investigate the structure- activity relationship (SAR)
of the lead compound.
Materials and methods
Chemistry
All the reagents obtained from commercial sources were used
without further purification. All reactions were run under an
inert atmosphere of nitrogen or argon. All the reactions were
monitored by thin layer chromatography (TLC) on silica gel 40
F254 (Merck, Darmstadt, Germany) coated on aluminum
plates. All 1H NMR spectra were recorded on a Bruker AM-
300 and 400 NMR spectrometer, Bruker BioSpin Corp., Ger-
many. Chemical shifts are in parts per million (ppm). Temper-
atures are reported in degrees Celsius (C) and are
uncorrected. Compounds were analysed for C, H, N, and ana-
lytical results obtained were within ±0.4% of the calculated
values for the formula shown. Molecular weights of the syn-
thesized compounds were checked by (Shimadzu, LCMS-
2020) ESI-MS method.
General procedure for the preparation of compound 2
To the stirred solution of (sub) phenylhydrazine (1.00 equiv) in
ethanol under N2 atmosphere added malonyl chlorideN
H
N
O
O
Cl
H3CO
O2N
HO
CD59
MTBMIC: 1.5uM
Fig. 1 – Reported antitubercular compound.(1.05 equiv) and the reaction mixture was stirred under reflux
conditions for 3 h. The reaction mixture was concentrated to
get a crude compound. The crude compound was purified by
column chromatography (EtOAc/Hexanes as eluent) to get a
pure compound (2).Preparation of 1-phenylpyrazolidine-3,5-dione
To the stirred solution of phenylhydrazine (3.0 g, 27.77 mmol)
in ethanol under N2 atmosphere was added malonyl chloride
(2.81 mL, 29.16 mmol), and the reaction mixture was stirred
under reflux conditions for 3 h. After completion of the reac-
tion by checking TLC, the reaction mixture was concentrated
to get a crude compound. The crude compound was directly
purified by column chromatography (EtOAc/Hexanes as elu-
ent) to get 1-phenylpyrazolidine-3,5-dione (3.60 g, 74%) as an
off-white solid. ESI-MS showed 177 [M+H]+ and was carried
to the next step.General procedure for the preparation of compound 3
Compound 2 (1.0 equiv) and aldehyde (1.0 equiv) were taken
in acetic acid and heated at 100 C for 4 h. The solids formed
in the reaction mixture were filtered and washed with water,
cold EtOH and Hexanes to get compound 3 as an off-white
solid.4-Benzylidene-1-phenylpyrazolidine-3,5-dione (3a)
1-phenylpyrazolidine-3,5-dione (0.6 g, 3.41 mmol) and Benzal-
dehyde (0.34 mL, 3.41 mmol) were taken in acetic acid and
heated at 100 C for 4 h. The solids formed in the reaction
mixture were filtered and washed with water, cold EtOH and
hexanes to get (Z)-4-benzylidene-1-phenylpyrazolidine-3,5-
dione (704 mg, 78%) as an off-white solid. MS(ESI) m/z 265
[M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.41 (bs, 1H), 8.49
(d, J = 7.2 Hz, 2H), 7.99–7.40 (m, 8H), 7.19 (t, J = 7.6 Hz, 1H). Anal
calcd for C16H12N2O2: C, 72.72; H, 4.58; N, 10.60%. Found C,
72.81; H, 4.61; N, 10.71%.4-(4-Hydroxybenzylidene)-1-phenylpyrazolidine-3,5-dione
(3b)
MS(ESI) m/z 281 [M+H]+. 1H NMR (400 MHz, DMSO-d6):
d 11.23 (s, 1H), 9.54 (s, 1H), 7.92–7.81 (m, 4H), 7.72 (s, 1H),
7.69(d, J = 7.2 Hz, 2H), 7.63–7.56 (m, 3H). Anal calcd for
C16H12N2O3: C, 68.56; H, 4.32; N, 9.99%. Found C, 68.61;
H, 4.41; N, 10.03%.4-(4-Methoxybenzylidene)-1-phenylpyrazolidine-3,5-dione
(3c)
MS(ESI) m/z 295 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.10
(s, 1H), 8.08 (d, J = 7.2 Hz, 2H), 7.90 (d, J = 7.6 Hz, 2H), 7.81 (s,
1H), 7.77–7.63 (m, 3H), 7.54 (d, J = 8.0 Hz, 2H), 4.03 (s, 3H). Anal
calcd for C17H14N2O3: C, 69.38; H, 4.79; N, 9.52%. Found C,
69.41; H, 4.91; N, 9.58%.
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 3 ( 2 0 1 4 ) 1 1 7 –1 2 6 1194-(4-(Benzyloxy)benzylidene)-1-phenylpyrazolidine-3,5-dione
(3d)
MS(ESI) m/z 371 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.22
(s, 1H), 7.92 (d, J = 7.6 Hz, 2H), 7.81–7.77 (m, 6H), 7.63 (d,
J = 7.6 Hz, 2H), 7.58–7.49 (m, 5H), 5.20 (s, 2H). Anal calcd for
C23H18N2O3: C, 74.58; H, 4.90; N, 7.56%. Found C, 74.61; H,
4.99; N, 7.63%.4-(2-(Benzyloxy)benzylidene)-1-phenylpyrazolidine-3,5-dione
(3e)
MS(ESI) m/z 371 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.28
(s, 1H), 7.92–7.81 (m, 4H), 7.77 (s, 1H), 7.72–7.58 (m, 6H), 7.54–
7.45 (m, 4H), 5.10 (s, 2H). Anal calcd for C23H18N2O3: C, 74.58;
H, 4.90; N, 7.56%. Found C, 74.63; H, 4.93; N, 7.68%.4-(4-Methylbenzylidene)-1-phenylpyrazolidine-3,5-dione (3f)
MS(ESI) m/z 279 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 10.91
(s, 1H), 7.99 (d, J = 7.2 Hz, 2H), 7.81 (d, J = 7.2 Hz, 2H), 7.78 (s,
1H), 7.72–7.58 (m, 3H), 7.48 (d, J = 8.0 Hz, 2H), 2.63 (s, 3H). Anal
calcd for C17H14N2O2: C, 73.37; H, 5.07; N, 10.07%. Found C,
73.41; H, 5.11; N, 10.15%.1-Phenyl-4-(3,4,5-trimethoxybenzylidene)pyrazolidine-3,
5-dione (3g)
MS(ESI) m/z 355 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.01
(s, 1H), 7.92 (d, J = 7.6 Hz, 2H), 7.81 (t, J = 6.8 Hz, 2H), 7.63 (t,
J = 6.8 Hz, 1H), 7.54 (s, 1H), 7.36 (s, 2H), 3.94 (s, 9H). Anal calcd
for C19H18N2O5: C, 64.40; H, 5.12; N, 7.91%. Found C, 64.47; H,
5.21; N, 7.99%.4-(4-Fluorobenzylidene)-1-phenylpyrazolidine-3,5-dione (3h)
MS(ESI) m/z showed 283 [M+H]+. 1H NMR (400 MHz, DMSO-d6):
d 11.61 (s, 1H), 8.10 (s, 1H), 7.81(d, J = 7.2 Hz, 2H), 7.72–7.54 (m,
5H), 7.49 (d, J = 7.6 Hz, 2H). Anal calcd for C16H11FN2O2: C,
68.08; H, 3.93; N, 9.92%. Found C, 68.11; H, 3.99; N, 9.97%.4-(2-Chlorobenzylidene)-1-phenylpyrazolidine-3,5-dione (3i)
MS(ESI) m/z 299 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.31
(s, 1H), 7.99 (s, 1H), 7.81 (d, J = 7.6 Hz, 1H), 7.78–7.60 (m, 7H),
7.49 (t, 1H). Anal calcd for C16H11ClN2O2: C, 64.33; H, 3.71; N,
9.38%. Found C, 64.36; H, 3.76; N, 9.43%.4-(4-Chlorobenzylidene)-1-phenylpyrazolidine-3,5-dione (3j)
MS(ESI) m/z 299 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.70
(s, 1H), 8.13 (s, 1H), 7.89 (d, J = 7.2 Hz, 2H), 7.76–7.49 (m, 7H).
Anal calcd for C16H11ClN2O2: C, 64.33; H, 3.71; N, 9.38%. Found
C, 64.36; H, 3.79; N, 9.43%.4-(2-Bromobenzylidene)-1-phenylpyrazolidine-3,5-dione (3k)
MS(ESI) m/z 343 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.23
(s, 1H), 8.01 (s, 1H), 7.89 (d, J = 7.2 Hz, 1H), 7.81–7.63 (m, 7H),
7.54 (t, 1H). Anal calcd for C16H11BrN2O2: C, 56.00; H, 3.23; N,
8.16%. Found C, 56.10; H, 3.31; N, 8.21%.
4-(4-Bromobenzylidene)-1-phenylpyrazolidine-3,5-dione (3l)
MS(ESI) m/z 343 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.41
(s, 1H), 7.91(d, J = 7.2 Hz, 2H), 7.82 (d, J = 7.6 Hz, 2H), 7.78 (s,
1H), 7.72–7.63 (m, 3H), 7.49 (d, J = 7.2 Hz, 2H). Anal calcd for
C16H11BrN2O2: C, 56.00; H, 3.23; N, 8.16%. Found C, 56.12; H,
3.33; N, 8.22%.4-(3-Nitrobenzylidene)-1-phenylpyrazolidine-3,5-dione (3m)
MS(ESI) m/z 310 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.43
(s, 1H), 8.45 (s, 1H), 7.99 (d, J = 6.8 Hz, 1H), 7.92 (d, J = 7.2 Hz,
1H), 7.86 (s, 1H), 7.81 (d, J = 7.6 Hz, 2H), 7.72 (t, J = 6.8 Hz, 1H),
7.68–7.54 (m, 3H). Anal calcd for C16H11N3O4: C, 62.14; H,
3.58; N, 13.59%. Found C, 62.21; H, 3.60; N, 13.63%.4-(Furan-2-ylmethylene)-1-phenylpyrazolidine-3,5-dione (3n)
MS(ESI) m/z 255 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.32
(s, 1H), 8.01 (d, J = 7.2 Hz, 1H), 7.92 (s, 1H), 7.81–7.74 (m, 3H),
7.63 (t, J = 7.2 Hz, 1H), 7.58–7.45 (m, 3H). Anal calcd for
C14H10N2O3: C, 66.14; H, 3.96; N, 11.02%. Found C, 66.26; H,
4.03; N, 11.07%.4-((5-Nitrofuran-2-yl)methylene)-1-phenylpyrazolidine-3,
5-dione (3o)
MS(ESI) m/z 300 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.24
(s, 1H), 8.12 (d, J = 7.2 Hz, 1H), 7.89 (s, 1H), 7.78 (d, J = 7.2 Hz,
2H), 7.72 (t, J = 6.8 Hz, 1H), 7.62–7.49 (m, 3H). Anal calcd for
C14H9N3O5: C, 56.19; H, 3.03; N, 14.04%. Found C, 56.26; H,
3.13; N, 14.08%.4-Benzylidene-1-(4-chlorophenyl)pyrazolidine-3,5-dione (4a)
MS(ESI) m/z 299 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.22
(bs, 1H), 8.35 (d, J = 7.2 Hz, 2H), 8.10–7.81 (m, 4H), 7.72 (d,
J = 6.8 Hz, 2H), 7.63–7.54 (m, 2H). Anal calcd for C16H11ClN2O2:
C, 64.33; H, 3.71; N, 9.38%. Found C, 64.41; H, 3.76; N, 9.43%.1-(4-Chlorophenyl)-4-(4-hydroxybenzylidene)pyrazolidine-
3,5-dione (4b)
MS(ESI) m/z 315 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.10
(s, 1H), 9.63 (s, 1H), 8.01 (d, J = 7.6 Hz, 2H), 7.92–7.77 (m, 5H),
7.63 (d, J = 7.2 Hz, 2H). Anal calcd for C16H11ClN2O3: C, 61.06;
H, 3.52; N, 8.90%. Found C, 61.12; H, 3.56; N, 8.98%.
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3,5-dione (4c)
MS(ESI) m/z 329 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.32
(s, 1H), 7.92 (d, J = 7.6 Hz, 2H), 7.81 (d, J = 7.6 Hz, 2H), 7.76 (s,
1H), 7.65 (d, J = 7.6 Hz, 2H), 7.54 (d, J = 7.6 Hz, 2H), 4.12 (s, 3H).
Anal calcd for C17H13ClN2O3: C, 62.11; H, 3.99; N, 8.52%. Found
C, 62.21; H, 4.05; N, 8.64%.
4-(4-(Benzyloxy)benzylidene)-1-(4-chlorophenyl)pyrazolidine-
3,5-dione (4d)
MS(ESI) m/z 405 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.45
(s, 1H), 8.02 (d, J = 7.2 Hz, 2H), 7.92 (d, J = 7.6 Hz, 2H), 7.87–
7.72 (m, 4H), 7.63–7.58 (m, 4H), 7.45 (d, J = 8.0 Hz, 2H), 5.13 (s,
2H). Anal calcd for C23H17ClN2O3: C, 68.23; H, 4.23; N, 6.92%.
Found C, 68.31; H, 4.29; N, 6.99%.
4-(2-(Benzyloxy)benzylidene)-1-(4-chlorophenyl)pyrazolidine-
3,5-dione (4e)
MS(ESI) m/z 405 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.43
(s, 1H), 8.12–7.81 (m, 6H), 7.77–7.63 (m, 6H), 7.58–7.49 (m, 2H),
5.22 (s, 2H). Anal calcd for C23H17ClN2O3: C, 68.23; H, 4.23; N,
6.92%. Found C, 68.35; H, 4.26; N, 7.02%.
1-(4-Chlorophenyl)-4-(4-methylbenzylidene)pyrazolidine-3,
5-dione (4f)
MS(ESI) m/z 313 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.31
(s, 1H), 7.92 (d, J = 7.2 Hz, 2H), 7.84 (d, J = 7.2 Hz, 2H), 7.78 (s,
1H), 7.71 (d, J = 7.6 Hz, 2H), 7.63 (d, J = 7.6 Hz, 2H), 2.58 (s, 3H).
Anal calcd for C17H13ClN2O2: C, 65.29; H, 4.19; N, 8.96%. Found
C, 65.41; H, 4.21; N, 9.07%.
1-(4-Chlorophenyl)-4-(3,4,5-
trimethoxybenzylidene)pyrazolidine-3,5-dione (4g)
MS(ESI) m/z 389 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.24
(s, 1H), 7.99(d, J = 8.0 Hz, 2H), 7.83 (d, J = 7.6 Hz, 2H), 7.72 (s,
1H), 7.58 (s, 2H), 3.96 (s, 9H). Anal calcd for C19H17ClN2O5: C,
58.69; H, 4.41; N, 7.21%. Found C, 58.72; H, 4.49; N, 7.30%.
1-(4-Chlorophenyl)-4-(4-fluorobenzylidene)pyrazolidine-3,
5-dione (4h)
MS(ESI) m/z 317 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.61
(s, 1H), 7.99 (d, J = 7.2 Hz, 2H), 7.81 (d, J = 7.2 Hz, 2H), 7.72 (d,
J = 7.2 Hz, 2H), 7.65 (s, 1H), 7.49 (d, J = 7.2 Hz, 2H). Anal calcd
for C16H10ClFN2O2: C, 60.68; H, 3.18; N, 8.85%. Found C, 60.72;
H, 3.21; N, 8.91%.
4-(2-Chlorobenzylidene)-1-(4-chlorophenyl)pyrazolidine-3,
5-dione (4i)
MS(ESI) m/z 333 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 10.31
(s, 1H), 7.89 (d, J = 7.2 Hz, 2H), 7.81 (s, 1H), 7.76–7.58 (m, 6H).
Anal calcd for C16H10Cl2N2O2: C, 57.68; H, 3.03; N, 8.41%. Found
C, 57.70; H, 3.07; N, 8.54%.4-(4-Chlorobenzylidene)-1-(4-chlorophenyl)pyrazolidine-3,
5-dione (4j)
MS(ESI) m/z 333 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.70
(s, 1H), 8.01 (d, J = 7.2 Hz, 2H), 7.92 (d, J = 7.2 Hz, 2H), 7.72 (d,
J = 7.2 Hz, 2H), 7.63 (s, 1H), 7.54 (d, J = 7.2 Hz, 2H). Anal calcd
for C16H10Cl2N2O2: C, 57.68; H, 3.03; N, 8.41%. Found C, 57.72;
H, 3.12; N, 8.53%.
4-(2-Bromobenzylidene)-1-(4-chlorophenyl)pyrazolidine-3,
5-dione (4k)
MS(ESI) m/z 377 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.22
(s, 1H), 7.81 (d, J = 7.2 Hz, 1H), 7.77 (s, 1H), 7.72–7.58 (m, 6H),
7.47 (d, J = 7.2 Hz, 1H). Anal calcd for C16H10BrClN2O2: C,
50.89; H, 2.67; N, 7.42%. Found C, 50.94; H, 2.74; N, 7.47%.
4-(4-Bromobenzylidene)-1-(4-chlorophenyl)pyrazolidine-3,
5-dione (4l)
MS(ESI) m/z 377 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.43
(s, 1H), 8.04 (d, J = 7.2 Hz, 2H), 7.92 (d, J = 7.6 Hz, 2H), 7.69 (d,
J = 8.0 Hz, 2H), 7.58 (s, 1H), 7.45 (d, J = 7.6 Hz, 2H). Anal calcd
for C16H10BrClN2O2: C, 50.89; H, 2.67; N, 7.42%. Found C,
50.94; H, 2.72; N, 7.54%.
1-(4-Chlorophenyl)-4-(3-nitrobenzylidene)pyrazolidine-3,
5-dione (4m)
MS(ESI) m/z 344 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.34
(s, 1H), 8.49 (s, 1H), 8.08–7.94 (m, 3H), 7.83 (d, J = 7.6 Hz, 2H),
7.76 (t, J = 6.8 Hz, 1H), 7.72 (d, J = 7.2 Hz, 2H). Anal calcd for C16-
H10ClN3O4: C, 55.91; H, 2.93; N, 12.23%. Found C, 55.97; H, 2.98;
N, 12.34%.
1-(4-Chlorophenyl)-4-(furan-2-ylmethylene)pyrazolidine-3,
5-dione (4n)
MS(ESI) m/z 289 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.43
(s, 1H), 8.12 (d, J = 7.2 Hz, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.89–
7.79 (m, 3H), 7.76 (t, J = 6.8 Hz, 1H) 7.72 (d, J = 7.2 Hz, 2H). Anal
calcd for C14H9ClN2O3: C, 58.25; H, 3.14; N, 9.70%. Found C,
58.31; H, 3.21; N, 9.81%.
1-(4-Chlorophenyl)-4-((5-nitrofuran-2-yl)methylene)
pyrazolidine-3,5-dione (4o)
MS(ESI) m/z 334 [M+H]+. 1H NMR (400 MHz, DMSO-d6): d 11.49
(s, 1H), 8.28 (d, J = 7.2 Hz, 1H), 8.01 (d, J = 7.6 Hz, 1H), 7.89 (d,
J = 8.0 Hz, 2H), 7.81 (s, 1H), 7.74 (d, J = 7.6 Hz, 2H). Anal calcd
for C14H8ClN3O5: C, 50.39; H, 2.42; N, 12.59%. Found C, 50.45;
H, 2.49; N, 12.71%.
Biological evaluation
In vitro MTB MABA assay
Briefly, the inoculum was prepared from fresh LJ medium re-
suspended in 7H9 medium (7H9 broth, 0.1% casitone, 0.5%
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 3 ( 2 0 1 4 ) 1 1 7 –1 2 6 121glycerol, supplemented oleic acid, albumin, dextrose, and cat-
alase [OADC]), adjusted to a McFarland tube No. 1, and diluted
1:20; 100 ll was used as inoculum. Each drug stock solution
was thawed and diluted in 7H9-S at fourfold the final highest
concentration tested. Serial twofold dilutions of each drug
were prepared directly in a sterile 96-well microtiter plate
using 100 ll 7H9-S. A growth control containing no antibiotic
and a sterile control were also prepared on each plate. Sterile
water was added to all perimeter wells to avoid evaporation
during the incubation. The plate was covered, sealed in plas-
tic bags and incubated at 37 C in normal atmosphere. After
7 days of incubation, 30 ll of alamar blue solution was added
to each well, and the plate was re-incubated overnight. A
change in color from blue (oxidized state) to pink (reduced)
indicated the growth of bacteria, and the MIC was defined
as the lowest concentration of drug that prevented this
change in color.In vitro cytotoxicity screening
The safety profile of all the compounds were examined by
evaluating their in vitro cytotoxicity against RAW 264.7 cell
line at the concentration of 100 lM. After 72 h of exposure,
viability was assessed on the basis of cellular conversion of
MTT into a formazan product using the Promega Cell Titer
96 non-radioactive cell proliferation assay.
In vitro MTB Pantothenate synthetase screening
To each well of a 96-well plate, 60 lL of PS reagent mix was
added, including NADH, pantoic acid, b-alanine, ATP, phos-
phoenolpyruvate, MgCl2, myokinase, pyruvate kinase, and
lactate dehydrogenase in buffer. Compounds were then
added to plates in 1-lL volumes. The reaction was initiated
with the addition of 39 lL of PS, diluted in buffer. The final
concentrations in the reaction were 0.4 mM NADH, 5 mM
pantoic acid, 10 mM MgCl2, 5 mM b-alanine, 10 mM ATP,
1 mM potassium phosphoenolpyruvate, and 18 units/mL each
of chicken muscle myokinase, rabbit muscle pyruvate kinase,
and rabbit muscle lactate dehydrogenase diluted in 100 mM
HEPES buffer (pH 7.8), 1% DMSO, and 5 lg/mL PS in a final vol-
ume of 100 lL. The test plate was immediately transferred to a
microplate reader, and absorbance was measured at 340 nm
every 12 s for 120 s. Each plate had 16 control wells in the 2
outside columns, of which 12 contained the complete reac-
tion mixture with DMSO carrier control (full reaction) and 4
without the addition of PS (background).% Inhib calculated
using the following formula: 100 * 1  compound rate  back-
ground rate/full reaction rate  background rate.
In vitro MTB L-Alanine dehydrogenase (AlaDH) enzyme
inhibition assay
To each well of a 96-well plate, reaction mixture consisted of
125 mM glycine/KOH (pH 10.2), 100 mM L-alanine, 1.25 mM
NAD+ and 6.026 pM of MTB-AlaDH in a final volume of
200 ll diluted in 125 mM glycine/KOH (pH 10.2). Compounds
were then added to plates. The reaction was initiated with
the addition of 10lL of ADH, diluted in buffer. Enzymaticactivity was measured by the rate of the production of NADH
that accompanies the conversion of alanine to pyruvate in the
oxidative deamination. The reaction components, except
MTB-AlaDH, were mixed in the well and the background reac-
tion was measured; MTB-AlaDH was then added and the reac-
tion kinetics was monitored. The same method was followed
for testing the designed inhibitors with different concentra-
tions. All measurements were performed at 340 nm with
heat-controlled Perkin Elmer Victor V3 spectrophotometer.
In vitro MTB lysine amino transferase (LAT) enzyme
inhibition assay
MTB LAT activity was determined by the detection of piperi-
dine 6-carboxylate. Briefly, 15 mM enzyme solution was
added to 1.0 ml 200 mM phosphate buffer pH 7.2 containing
1 mM L-lysine–HCl, 1 mM a-ketoglutarate and 15 mM PLP.
The mixture was incubated at 310 K for 1 h. The reaction
was terminated by the addition of 500 ml 10% trichloroacetic
acid in ethanol. Piperidine 6-carboxylate was detected by
measuring the color intensity of its adduct with o-amino-
benzaldehyde spectroscopically at 465 nm.Results
Biological evaluation
The compounds were screened for their in vitro antimycobac-
terial activity against M. tuberculosis H37Rv by microplate ala-
mar blue assay method [5] for the determination of MIC in
duplicate. The minimum inhibitory concentration (MIC) is de-
fined as the minimum concentration of compound required
to give complete inhibition of bacterial growth. MICs of the
synthesized compounds along with the standard drugs for
comparison are reported (Table 1).
Most of the tested compounds were not cytotoxic to RAW
264.7 cells and their percentage growth inhibitions were re-
ported in Table 1. To explore the possible mechanism/target
of these active antitubercular compounds, 20 compounds
with MIC of 625 lM were selected and screened against
MTB Pantothenate synthetase (PS), lysine amino transferase
(LAT) and Alanine dehydrogenase enzymes (AlaDH). PS (EC
6.3.2.1), encoded by the panC gene, catalyzes the essential
adenosine triphosphate (ATP)-dependent condensation of D-
pantoate and b-alanine to form pantothenate in bacteria [6],
and IC50 values were reported in Table 1.
Discussion
Chemistry
The target molecules were synthesized by two-step synthetic
protocol (Fig. 2); in the first step, the (sub)phenylhydrazine
was initially treated with malonic acid using methanol as a sol-
vent under reflux conditions for 2 h. These reactions were also
carried with malonyl chloride instead of malonic acid in etha-
nol as a solvent under reflux conditions for 3 h; more yields
were observed when the reactions were carried using malonyl
chloride. The commercially available 4-chlorophenylhydra-
Table 1 – Biological activities of synthesized compounds.
3a-o 4a-o
N
HN O
O R2
Cl
N
HN O
O R2
Comp. R2 Yield (%) MP (C) MTB MIC in lM IC50 in lM
PanC
IC50 in lM
AlaDH
IC50 in lM
LAT
Cytotoxicity
at 50 lMa
3a Phenyl 78 235–236 188.6 NT NT NT NT
3b 4-Hydroxyphenyl 81 210–211 111.2 NT NT NT NT
3c 4-Methoxyphenyl 65 198–199 84.74 NT NT NT NT
3d 4-Benzyloxyphenyl 71 205–206 67.38 NT NT NT NT
3e 2-Benzyloxyphenyl 69 213–214 134.77 NT NT NT NT
3f 4-Methylphenyl 63 240–241 179.21 NT NT NT NT
3g 3,4,5-Trimethoxyphenyl 79 260–261 140.84 NT NT NT NT
3h 4-Fluorophenyl 54 191–192 5.53 5.47 ± 0.24 >50 50 ± 3.12 22.16
3i 2-Chlorophenyl 61 204–205 5.21 >50 >50 11.45 ± 0.16 18.12
3j 4-Chlorophenyl 72 241–242 5.21 >50 >50 29.92 ± 1.16 20.86
3k 2-Bromophenyl 65 187–188 4.54 >50 10.63 ± 0.16 >50 18.42
3l 4-Bromophenyl 70 178–179 18.22 >50 >50 21.40 ± 1.62 24.62
3m 3-Nitrophenyl 63 234–235 10.08 50 ± 1.32 >50 40.64 ± 3.24 30.16
3n Furan-2-yl 57 245–246 24.5 >50 8.14 ± 0.09 >50 26.52
3o 5-Nitrofuran-2-yl 76 225–226 10.41 6.98 ± 0.12 >50 40.43 ± 2.12 28.32
4a Phenyl 66 211–213 20.84 12.51 ± 0.08 22.39 ± 0.38 50 ± 2.68 16.12
4b 4-Hydroxyphenyl 52 214–215 15.87 4.18 ± 0.16 >50 >50 12.28
4c 4-Methoxyphenyl 76 231–232 37.99 NT NT NT NT
4d 4-Benzyloxyphenyl 81 241–242 7.71 >50 8.97 ± 0.34 13.60 ± 0.92 14.56
4e 2-Benzyloxyphenyl 69 247–248 41.15 NT NT NT NT
4f 4-Methylphenyl 74 229–231 53.31 NT NT NT NT
4g 3,4,5-Trimethoxyphenyl 69 260–261 16.06 3.73 ± 0.11 15.84 ± 0.46 >50 11.86
4h 4-Fluorophenyl 54 219–220 7.88 6.14 ± 0.33 >50 >50
4i 2-Chlorophenyl 64 222–223 4.68 12.98 ± 0.30 30.02 ± 0.64 19.94 ± 0.37 27.42
4j 4-Chlorophenyl 67 261–262 7.50 50 ± 2.08 50 ± 2.07 19.92 ± 0.12 23.14
4k 2-Bromophenyl 72 238–239 4.13 9.68 ± 0.26 19.47 ± 0.10 50 ± 2.41 26.12
4l 4-Bromophenyl 60 217–218 13.26 >50 50 ± 1.68 32.16 ± 1.60 18.12
4m 3-Nitrophenyl 63 223–224 18.16 >50 >50 30.42 ± 1.78 29.19
4n Furan-2-yl 58 235–236 17.30 >50 12.46 ± 1.04 >50 16.18
4o 5-Nitrofuran-2-yl 62 246–247 7.48 10.16 ± 0.09 >50 >50 24.53
Isoniazid 0.72 >50 >50 >50 NT
Rifampicin 0.24 >50 >50 >50 NT
Ethambutol 7.64 >50 >50 >50 NT
Pyrazinamide 50.77 >50 >50 >50 NT
Ciprofloxacin 4.71 >50 >50 >50 NT
NT indicates not tested.
a % inhibition against RAW 264.7 cells.
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first converted into a free amine by taking a compound in sat-
urated NaHCO3 solution, stirring for a few minutes, then
extracting the free amine with dichloromethane; the evapora-
tion of solvent produced the free amine. The obtained free
amine was treated with malonyl chloride using ethanol under
reflux conditions. The reaction mixture was concentrated and
triturated with water to obtain solid compound, the solids werewashed with water, cold ethanol, hexanes and dried in vacuo to
get compound 2. In the next step the active methylene group of
compound 2 (1-substituted-pyrazolidine-3,5-dione) was con-
densed with various substituted aldehydes to produce target
molecules (3a–o, 4a–o). Here the compound 2 was refluxed
and phenyl/heteroaryl aldehyde was substituted in acetic acid
for 4 h. The formation of solids was observed in the reaction
mixture; direct filtration of the reaction mixture and washing
1 2
a b
Reagents & Conditions: a: MalonylChloride, Ethanol, ref lux, 3 h;
b: R2CHO, AcOH, 100 °C, 4 h:
NH
R1
R1 R1R1 = H, Cl
H2N
N N
HN HN
O
O O
O R2
HCl
R1 = H: 3a-o,
R1 = Cl: 4a-o:
Fig. 2 – Synthetic protocol of the compounds.
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acid and then dried in a vacuum oven to get pure products with
ease of purification and with good yields. The purity of the syn-
thesized compounds was checked by TLC and elemental anal-
yses, and the structures were identified by spectral data. In the
nuclear magnetic resonance spectra (1H NMR), the signals of
the respective protons of the prepared pyrazolidinedione
derivatives were verified on the basis of their chemical shifts,
multiplicities, and coupling constants. The elemental analysis
results were within ±0.4% of the theoretical values.
Antitubercular activity
The synthesized compounds showed MIC’s ranging from 4.13–
188.6 lM; and 11 compounds showed promising activity with
MIC of less than 10 lM. When compared with original lead com-
pound CD59, all the compounds were found to be less active.
When compared with the standard first-line antitubercular
drug ethambutol (MIC of 7.64 lM), 9 compounds were found
to be more active, and when compared with pyrazinamide
(MIC of 50.77 lM), 22 compounds were more active. All the mol-
ecules were found be less active than isoniazid (MIC of 0.72 lM)
and rifampicin (MIC of 0.24 lM), but 3 compounds were more/
equally active than/as DNA gyrase inhibitor ciprofloxacin (MIC
of 4.71 lM). Among the compounds, 4-(2-bromobenzylidene)Fig. 3 – Binding pattern and protein ligand contac-1-(4-chlorophenyl)pyrazolidine-3,5-dione (4k) was found to be
the most active compound in vitro with MICs of 4.13 lM.
SAR study
To study the SAR, the compounds were prepared with varia-
tions in 1st and 4th positions. In N-1 position, two types of
modifications were tried: one with phenyl (3a–o) and the
other with 4-chlorophenyl (4a–o) groups as of lead compound.
In the C-4 position, molecules were prepared with a phenyl
ring with both electrons donating and with drawing groups
and also with a few heterocycles. The order of activity with re-
spect to N-1 position found 4-chlorophenyl (4a–o) to be more
potent than phenyl ring (3a–o). Phenyl ring at N-1 position
and at C-3 position phenyl ring with electron donating groups
(3b–g) were found to be more potent than phenyl ring with
electron withdrawing groups (3h–m). Compound 3a, without
any substituent on either of the phenyl rings, displayed an
MIC of 188.6 lM and serves as the standard for potency com-
parison. The activity of 3b improved 1.6 times (111.2 lM)
when a hydroxyl group was introduced at the 4th position
of the phenyl ring at C-3. Replacement of hydroxyl group with
methoxyl group (3c) further enhances the potency with MIC
of 84.74 and it further increases with MIC of 67.38 lM by intro-
ducing bulky benzyloxy group at 4th position (3d). Whereas
shifting benzyloxy group (3e) from 4th position to 2nd posi-
tion reduces activity two times with MIC of 134.77 lM. Intro-
duction of methyl group at 4th position (3f) does not change
much difference in activity when compared with compound
3a. Similarly, the introduction of three methoxyl groups (3g)
also does not show promising activity (140.84 lM). The intro-
duction of electron withdrawing group at 2nd, 3rd, and 4th
position (3h–m) generally enhances potency ten or more
times with MICs range from 4.54–18.22 lM. The introduction
of the furan ring (3n) improved 7.6 times (24.5 lM) more than
the compound 3a, and the further introduction of the nitro
group at the 5th position of the furan ring (3o) further en-
hances the activity (10.41 lM). In the case of a second set of
compounds (4a–o) with 4-chloro phenyl ring at N-1 position,
the introduction of the phenyl ring at the C-3 position (4a)
makes it 9 times more potent than compound 3a. The intro-ts of PanC with the most active compound 4g.
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oxy and methyl does not alter activity much except the 4-ben-
zyloxy group (4d) which was three times more potent than
compound 4a. The compound with the electron withdrawing
substituents (4h–m) was equal or less active than its counter-
part with the first set (3h–m).
Cytotoxicity
Compounds which showed MIC of less than 25 lM were fur-
ther examined for cytotoxicity (CC50) in a RAW 264.7 cell line
(mouse leukemic monocyte macrophage) at single concentra-
tion of 50 lM. After 72 h of exposure, viability was assessed on
the basis of cellular conversion of MTT into a formazan prod-
uct using the Promega Cell Titer 96 non-radioactive cell prolif-
eration assay. The most active anti-TB compound 4k has
shown toxicity of 26.12% at 50 lM with selectivity index of
>12.5 for MTB.
Enzyme inhibition and docking studies
Pantothenate is a key precursor of coenzyme A and acyl car-
rier protein, essential for many intracellular processes includ-
ing fatty acid metabolism, cell signalling, and synthesis of
polyketides and non-ribosomal peptides. Both microorgan-
isms and plants must synthesize pantothenate, while mam-
mals must obtain it from their diet, and its biosynthetic
pathway is not present. A PanC gene knockout (KO) of PS in
MTB results in a highly attenuated phenotype in immuno-
compromised SCID mice and in immunocompetent BALB/c
mice [7], whereas the DlysA DpanCD KO mutant exhibits sub-
stantially reduced replication and persistence [8]. The com-
pounds were assayed for MTB PS inhibition study, that
couples the AMP produced in the condensation of b-alanine
and pantoate with the reduction of NADH to NAD+ through
myokinase, pyruvate kinase and lactate dehydrogenase [6].
The IC50 of the screened compounds were reported in Table 1,
ten compounds inhibited MTB PS with IC50 of 650 lM. FiveFig. 4 – Binding pattern and protein ligand contacts ocompounds (3h, 3o, 4b, 4g and 4k) inhibited with IC50 of
<10 lM, and compound 1-(4-chlorophenyl)-4-(3,4,5-trimeth-
oxybenzylidene)pyrazolidine-3,5-dione (4g) emerged as more
potent with IC50 of 3.73 ± 0.11 lM. Compound 4-(4-fluoroben-
zylidene)-1-phenylpyrazolidine-3,5-dione (3h) showed good
correlation with MIC and IC50 of 5.53 and 5.47 ± 0.24 lM,
respectively. The crystal structure of the protein MTB PS in
complex with inhibitor 2-(2-(benzofuran-2ylsulfonylcarba-
moyl)-5-methoxy-1H-indol-1-yl) acetic acid (PDB code: 3IVX)
was retrieved from the protein data bank (PDB) and was used
for docking [9]. Analysis of the crystal structure of 3IVX
revealed two key hydrogen-bonding interactions, with the
carboxyl group to Met40 and His47 each. Also, it was making
hydrogen bonding interaction with Val187, Ser196, Ser197 and
His44. The protein crystal structure has two hydrophobic
pockets; one consists of Met40, Leu50, Phe157, Thr39 and
Pro38, and the other consists of Lys160, His44 and Gly46. First
the 2-(2-(benzofuran-2-ylsulfonylcarbamoyl)-5-methoxy-1H-
indol-1-yl) acetic acid is used to re-dock the active site cavity,
and it was showing a docking score of 9.03 and exhibiting
same hydrogen bonding interactions as shown in the crystal
structure of the protein. With the aim of getting insights into
the structural basis for the present MTB PS activity, the most
active compound 4g in the series was docked into the active
site of PanC enzyme. The most active compound 4g exhibited
the IC50 3.73 ± 0.11 lM, and it shows a good docking score of
7.72 kcal/mol. The active compound 4g showed four hydro-
gen bonding interactions with the relevant amino acid resi-
dues, such as HIE44, Ser197, Ser196 and Gln72. As shown in
Fig. 3, 4-chlorophenyl is occupying the one hydrophobic pock-
et. The compound also showed p-p stacking interaction with
HIE47 and HIE44 amino acid residues. Comparison of the en-
zyme inhibitory effectiveness of the compound 4g with glide
score suggests that the compound 4g adopts almost the same
conformation as reference compounds; also, out of five
important amino acid residues (HIE47, Met40, HIE44, Ser196
and Val187), it made an interaction with three amino acid res-f MTB AlaDH with the most active compound 3n.
Fig. 5 – Binding pattern and protein ligand contacts of MTB LAT with the most active compound 3i.
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against PanC.
AlaDH catalyze NAD(H)-dependent the oxidative deamina-
tion of L-alanine to pyruvate and ammonia (catabolic reac-
tion) or, in the reverse direction, the reductive amination of
pyruvate to L-alanine (biosynthetic reaction). A recent analy-
sis involving microarray and other data had identified this en-
zyme among the top three drug targets, especially against
persistence [10]. Enzymatic activity was measured by the rate
of production of NADH that accompanies the conversion of
alanine to pyruvate by oxidative deamination [11]. The IC50
of the screened compounds are reported in Table 1; ten
compounds inhibited MTB AlaDH with IC50 of 650 lM. Four
compounds (3k, 3n, 4d, and 4n) inhibited with IC50 of
<15 lM, and 4-(furan-2-ylmethylene)-1-phenylpyrazolidine-
3,5-dione (3n) was found to be a more potent compound with
IC50 of 8.14 ± 0.09 lM. The reported crystal structure of MTB
AlaDH (PDB code: 2VHW) consists of six chains, ABCDEF,
respectively. The subunit of MTB AlaDH is built up of two dis-
tinct domains: NAD+ binding domain and the substrate-bind-
ing domain. As there are no inhibitors reported for MTB
AlaDH, co-factor NAD+ bound with the protein along with
substrate pyruvate is used for docking studies in this report.
The reference ligand NAD+ was re-docked with the active site
residues of the MTB AlaDH protein to validate the active site
cavity. The compound exhibited the highest Glide score of
11.42 kcal/mol and it docked near the vicinity of amino acids
Asp270, Val298, Thr178, Ser220, Lys203, Asp198, Met301,
Ile267, Ser134, Leu240 and Ala179. Here, the binding analysis
of the most active compound 4-(furan-2-ylmethylene)-1-
phenylpyrazolidine-3,5-dione (3n) in the series is reported.
The most active compound 3n, IC50 8.14 ± 0.09 lM is showinga docking score of 5.79 only which showed the hydrogen
bonding interaction with important amino acids such as
Ala179, and Ala238, the compound that also makes the hydro-
phobic interaction with Leu130, Pro240, Leu240, Ala126,
Ala131, Ala176, Val239 and ILE199 (Fig. 4). The active com-
pound showing less hydrogen bonding as compared with
the reference ligand NAD+; this is because the compound
3n is small as compared with NAD+, and it occupies the smal-
ler active site cavity. Despite its small cavity, the compound
makes two hydrogen bonding interactions with important
amino acid residues such as Ala179 and Ala238; also in
addition, it fit well in the active site cavity. With this analysis,
it was observed that the active compound 3n showed less
hydrogen bonding interaction as compared with hydrophobic
interaction, which may indicate that hydrophobic interaction
plays an important role. The binding pattern of compound 3n
is depicted in Fig. 4.
Another enzyme important for long-term persistence is
MTB LAT. It is implicated in mycobacterial stress response
and is up-regulated approximately 40-fold in nutrient-starved
models designed to mimic the persistent/latent state of TB
[12]. LAT also plays an important role in adaptation to long-
term persistence in MTB; it catalyses an overall reaction
involving the transfer of the epsilon-amino group of L-lysine
to a-ketoglutarate to yield L-glutamate and alpha-aminoadi-
pate-D-semialdehyde and then to piperidine 6-carboxylate.
LAT activity was determined by the detection of reaction
product piperidine 6-carboxylate and it was detected by mea-
suring the color intensity of its adduct with o-amino benzal-
dehyde spectroscopically at 465 nm [13]. The IC50 of the
screened compounds were reported in Table 1; 13 compounds
inhibited MTB LAT with IC50 of 650 lM. Four compounds (3i,
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benzylidene)-1-phenylpyrazolidine-3,5-dione (3i) were found
to be more potent compounds with IC50 of 11.45 ± 0.16 lM.
The reported crystal structure of MTB LAT (PDB ID: 2CJH) con-
sists of one chain. In that protein substrate, a-ketoglutarate is
bound with PMP and is crystallized. As there are no significant
inhibitors reported which are co-crystallized with MTB LAT,
substrate a-ketoglutarate is bound with PMP and is used for
the docking studies in this report. First, the substrate a -keto-
glutarate is re-docked to the active site cavity and showed a
docking score of 5.28 and made two hydrogen bonding inter-
actions with Arg170, and one with Arg422, Lys300 and Gln274
amino acid residues. This study reports the binding analysis
of the most active compound 4-(2-chlorobenzylidine)-1-phen-
ylpyrazolidine-3,5-dione (3i) in the series. The most active
compound 3i showed a good docking score of 5.40, which
is higher than the a-ketoglutarate. The binding pattern of
the compound 3i is depicted in Fig. 5, and it clearly indicated
that the oxygen atom of the pyrazolidine ring makes a hydro-
gen bonding interaction with Lys300; another oxygen atom of
the pyrazolidine ring also makes a hydrogen bonding interac-
tion with Arg170, while the 2-chlorobenzylidine is surrounded
by some hydrophobic amino acid residues such as Val63,
Leu414, and Ile184. The NH atom of the pyrazolidine ring also
makes an interaction with PLP (Fig. 5). Based on this analysis,
it was observed that in compound 3i ‘pyrazolidine ring and 2-
chlorobenzylidine’ moiety is important for activity. The com-
pound 3i also fits well in the active site cavity, which is sur-
rounded by a few hydrophobic amino acids, such as Phe167,
Leu414, and Ile184. Compound 3i is also surrounded by these
hydrophobic amino acid residues.
Conclusion
In this study, the SAR of various inhibitors of MTB was de-
signed, synthesized and studied based on the reported lead
compound CD59. To explore the possible mechanism of ac-
tion of those active molecules, three MTB enzymes were
screened against them. Some of the compounds were active
against latent/persistent MTB targets; further screening of
these molecules required in vitro dormant MTB models.
Conflict of interest
No conflict of interest is perceived and none declared.
Acknowledgements
G.S. is thankful to CSIR-India for providing fellowship. D.S.
acknowledges University Grants Commission, New Delhi, In-
dia for UGC Research Award.R E F E R E N C E S[1] In World Health Organization Global Tuberculosis Control,
2012. Available at <http://www.who.int/tb/publications/
global_report/en/> (accessed 18th January 2014).
[2] In Multidrug and Extensively Drug-Resistant TB (M/XDR-TB):
Global Report on Surveillance and Response, 2010. Available
at <http://www.who.int/tb/publications/2010/978924599191/
en/index.html> (accessed 6th August 2013).
[3] D.J. Payne, M.N. Gwynn, D.J. Holmes, D.L. Pompliano, Drugs
for bad bugs: confronting the challenges of antibacterial
discovery, Nat. Rev. Drug. Disc. 6 (2007) 29–40.
[4] C. Vilcheze, A.D. Baughn, J. Tufariello, L.W. Leung, M. Kuo, C.F.
Basler, et al, Novel inhibitors of InhA efficiently kill
Mycobacterium tuberculosis under aerobic and anaerobic
conditions, Antimicrob. Agents Chemother. 55 (2011) 3889–
3898.
[5] S.G. Franzblau, R.S. Witzig, J.C. McLaughlin, P. Torres, G.
Madico, A. Hernandez, et al, Rapid, low-technology MIC
determination with clinical Mycobacterium tuberculosis
isolates by using the microplate Alamar Blue assay, J. Clin.
Microbiol. 36 (1998) 362–366.
[6] R. Zheng, J.S. Blanchard, Steady-state and pre-steady-state
kinetic analysis of Mycobacterium tuberculosis pantothenate
synthetase, Biochemistry 40 (2001) 12904–12912.
[7] V.K. Sambandamurthy, X. Wang, B. Chen, R.G. Russell, S.
Derrick, F.M. Collins, S.L. Morris, et al, A pantothenate
auxotroph of Mycobacterium tuberculosis is highly attenuated
and protects mice against tuberculosis, Nat. Med. 8 (2002)
1171–1174.
[8] V.K. Sambandamurthy, S.C. Derrick, K.V. Jalapathy, B. Chen,
R.G. Russell, S.L. Morris, et al, Long-term protection against
tuberculosis following vaccination with a severely attenuated
double lysine and pantothenate auxotroph of Mycobacterium
tuberculosis, Infect. Immun. 73 (2005) 1196–1203.
[9] A.W. Hung, H.L. Silvestre, S. Wen, A. Ciulli, T.L. Blundell, C.
Abell, et al, Application of fragment growing and fragment
linking to the discovery of inhibitors of Mycobacterium
tuberculosis pantothenate synthetase, Angew. Chem. Int. Ed.
48 (2009) 8452–8456.
[10] S. Hasan, S. Daugelat, P.S. Rao, M. Schreiber, Prioritizing
genomic drug targets in pathogens: application to
Mycobacterium tuberculosis, PLoS Comput. Biol. 2 (2006) 61.
[11] S.M. Tripathi, R. Ramachandran, Overexpression,
purification, crystallization and preliminary X-ray analysis of
Rv2780 from Mycobacterium tuberculosis H37Rv, Acta
Crystallogr., Sect. F: Struct. Biol. Cryst. Commun. 64 (2008)
367–370.
[12] J.C. Betts, P.T. Lukey, L.C. Robb, R.A. McAdam, K. Duncan,
Evaluation of a nutrient starvation model of Mycobacterium
tuberculosis persistence by gene and protein expression
profiling, Mol. Microbiol. 43 (2002) 717–731.
[13] S.M. Tripathi, R. Ramachandran, Overexpression, purification
and crystallization of lysine epsilon-aminotransferase
(Rv3290c) from Mycobacterium tuberculosis H37Rv, Acta
Crystallogr., Sect. F: Struct. Biol. Cryst. Commun. 62 (2006)
572–575.
